ALFA Filings
Every announcement, straight from the exchange
Every Syngene International earnings call announcement on NSE and BSE, newest first, each with its own page.
Time
7 announcements with these filters
Syngene reports a transitional quarter with sequential recovery but YoY declines due to the absence of the large Librela revenue stream.
Q2 FY27 revenue Rs 833 Cr (down 9% YoY, up 13% QoQ). Operating EBITDA margin 18% on forex hedge losses. PAT before exceptionals Rs 38 Cr (down 44% YoY). Focus on integrated CRDMO and first Bayview biologics deal.
Syngene reports Q1 FY27 revenue of Rs 736 Cr (-16% YoY). Performance was impacted by low offtake from a major client and forex losses.
Syngene FY26 results show muted 3% revenue growth due to 'Librela' destocking headwinds. Management indicates FY27 will be a transition year with flat revenue and mid-20s EBITDA margins.
Syngene faces a transition year in FY27 as the Librela de-stocking headwind masks underlying momentum in biologics and research services.
Syngene Q4 FY26 revenue grew 2% YoY to Rs 1,037 Cr with 29% EBITDA margin. Full year FY26 revenue reached Rs 3,739 Cr, driven by integrated CRDMO services.
Syngene reported Q4 FY26 revenue of ₹1,037 Cr (up 2% YoY) and FY26 revenue of ₹3,739 Cr (up 3% YoY). Management announced leadership transitions including a new CEO effective July 2026.